Free Trial

RadNet (RDNT) Stock Price, News & Analysis

RadNet logo
$72.70 +1.32 (+1.85%)
(As of 12/20/2024 05:31 PM ET)

About RadNet Stock (NASDAQ:RDNT)

Key Stats

Today's Range
$70.15
$72.85
50-Day Range
$65.04
$86.38
52-Week Range
$33.44
$93.65
Volume
1.22 million shs
Average Volume
550,379 shs
Market Capitalization
$5.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$84.75
Consensus Rating
Buy

Company Overview

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

RadNet Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
77th Percentile Overall Score

RDNT MarketRank™: 

RadNet scored higher than 77% of companies evaluated by MarketBeat, and ranked 219th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    RadNet has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    RadNet has only been the subject of 4 research reports in the past 90 days.

  • Read more about RadNet's stock forecast and price target.
  • Earnings Growth

    Earnings for RadNet are expected to grow by 5.00% in the coming year, from $0.60 to $0.63 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of RadNet is -1,038.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of RadNet is -1,038.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    RadNet has a P/B Ratio of 6.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.93% of the outstanding shares of RadNet have been sold short.
  • Short Interest Ratio / Days to Cover

    RadNet has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in RadNet has recently increased by 4.89%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    RadNet does not currently pay a dividend.

  • Dividend Growth

    RadNet does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.93% of the outstanding shares of RadNet have been sold short.
  • Short Interest Ratio / Days to Cover

    RadNet has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in RadNet has recently increased by 4.89%, indicating that investor sentiment is decreasing.
  • News Sentiment

    RadNet has a news sentiment score of 1.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for RadNet this week, compared to 6 articles on an average week.
  • Search Interest

    5 people have searched for RDNT on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added RadNet to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, RadNet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,088,855.00 in company stock.

  • Percentage Held by Insiders

    Only 5.12% of the stock of RadNet is held by insiders.

  • Percentage Held by Institutions

    77.90% of the stock of RadNet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about RadNet's insider trading history.
Receive RDNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RadNet and its competitors with MarketBeat's FREE daily newsletter.

RDNT Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.
RadNet price target raised to $100 from $82 at Jefferies
RadNet’s DeepHealth launches new AI-powered solutions at RSNA 2024
See More Headlines

RDNT Stock Analysis - Frequently Asked Questions

RadNet's stock was trading at $34.77 at the beginning of the year. Since then, RDNT shares have increased by 109.1% and is now trading at $72.70.
View the best growth stocks for 2024 here
.

RadNet, Inc. (NASDAQ:RDNT) issued its quarterly earnings data on Wednesday, August, 7th. The medical research company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by $0.01. The firm's revenue was up 13.9% compared to the same quarter last year.

RadNet's top institutional shareholders include State Street Corp (3.30%), RTW Investments LP (2.44%), Geode Capital Management LLC (2.10%) and Principal Financial Group Inc. (2.04%). Insiders that own company stock include Alma Gregory Sorensen, Norman R Hames, David L Swartz, Ranjan Jayanathan, Lawrence L Levitt, Mark Stolper, David Jeffrey Katz, Michael N Murdock, Christine Nayoma Gordon and Gregory E Spurlock.
View institutional ownership trends
.

Shares of RDNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that RadNet investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/07/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:RDNT
Employees
10,288
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$84.75
High Stock Price Target
$100.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+16.6%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$3.04 million
Pretax Margin
2.05%

Debt

Sales & Book Value

Annual Sales
$1.77 billion
Cash Flow
$3.01 per share
Book Value
$11.79 per share

Miscellaneous

Free Float
70,237,000
Market Cap
$5.38 billion
Optionable
Optionable
Beta
1.77

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:RDNT) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners